Liposomal gene transfer effectively enhances dermal and epidermal regeneration in burned rodents. To advance this treatment to clinical studies, we investigated the efficacy of liposomal gene transfer in a clinically relevant porcine wound model. Mimicking the clinical scenario, six female Yorkshire pigs (40-50 kg) received up to 12 burns of 50 cm 2 area that were fully excised and covered with skin autograft meshed at 4:1 ratio 24 h post-burn. Animals received control injections (empty liposomes), liposomes (DMRIE-C) containing 1 mg LacZ-cDNA, or liposomes (DMRIE-C) with 1 mg of platelet-derived growth factor (PDGF)-cDNA, or the naked PDGF gene. Serial biopsies were taken from different wound sites at multiple time points up to 12 days post-wounding. Transfection efficacy and transfection rate of LacZ and localization of b-gal were determined by immunohistochemical and immunofluorescent techniques. RT-PCR and multiplex protein analysis (ELISA) were used to measure levels of growth factor mRNA transcribed and growth factor protein translated. Wound re-epithelialization and graft adhesion was evaluated using planimetric analysis and clinical scores. We found that peak transfection of liposomal b-galactosidase occurred on day 2, with a fluorescence increase of 154% to baseline (Po0.001). Transfection intensity dropped to 115% above baseline on day 4 (Po0.001) and 109% on day 7. Immunohistochemistry showed a maximum transfection rate of 34% of cells in wound tissue. Gene transfer of liposomal PDGF-cDNA resulted in increased PDGF-mRNA and protein expression on days 2 and 4, and accelerated wound re-epithlialization as well as graft adhesion on day 9 (Po0.05). In this study, we showed that liposomal cDNA gene transfer is possible in a porcine wound model, and by using PDGF-cDNA we further showed that dermal and epidermal regeneration can be improved. These data indicate that liposomal gene transfer can be a new therapeutic approach to improve wound healing in humans.
Introduction
Use of transient gene therapy in wound healing has recently come to the attention of burn care specialists worldwide. The combination of growth factor therapy and gene therapy has led to the development of genes for a modulation of acute and chronic wound healing. 1 Successful delivery of growth factor genes to the wound and skin harbors many pitfalls and requires welldesigned delivery systems to ensure an effective transfection. Factors influencing effective transfection include damage to the gene construct due to the harsh environment of the wound bed, reliability of the vehicle carrying genes for transfection, and appropriately targeted gene delivery.
Recent advances in cellular and molecular biology have greatly expanded our understanding of the role of growth factors in wound repair and tissue regeneration. Growth factors are synthesized and secreted by many cell types involved in wound repair including inflammatory cells, fibroblasts, platelets, epithelial cells, and vascular endothelial cells. 2 Recombinant growth factors have been used as a means for increasing local concentrations of growth factors within wounds 3; however, they are more expensive, greatly labor intensive to produce, and less efficacious when compared with plasmids or vectors used for gene transfer. Therefore, gene therapy is emerging as an important method for delivery of growth factors to wounds. 1 As a vector for gene therapy, liposomes have become attractive due to their non-viral composition, safety, stability, and ability to interact with the cell membrane. 1 They are self-assembling particles that provide a protective coat for cDNA, whereas naked cDNA has no protection from DNAase. 4 Until recently, it was essentially impossible to transfect dermal and epidermal cells using a liposomal vector in a porcine model. However, as pig skin resembles the human skin, pre-clinical trials to study the efficacy of liposomal gene transfer are required in this model. We therefore set up this study to determine whether liposomal gene transfer is possible in a porcine wound model, 5 and to determine whether gene transfer of platelet-derived growth factor (PDGF)-cDNA can effectively alter dermal and epidermal regeneration.
Results

Gene transfer efficiency
Immunohistochemical analysis showed that LacZ gene transfer and b-galactosidase expression was successful in wounds treated with liposomal vectors (Figure 1 ). Wounds treated with liposomal cDNA showed a peak in the amount of transfected cells at day 2 (29±7%). Percentage of transfected cells remained steady on day 4 (27±3%) and day 7 (26±2%). A modest decline in transfection percentage was seen on day 9 (23 ± 3%) ( Figure 1 ).
Immunofluorescence detection of gene transfection ( Figure 2 ) via measurement of b-galactosidase expression showed increased expression at earlier time points and diminished expression at later time points. In wounds treated with liposomal vectors, day 2 had the highest amount of expression (13 200 arbitrary intensity units [AIU]), which represents a 158% increase over fluorescence levels in controls slides. As in our immunohistochemical analysis, day 4 and day 7 maintained a steady transfection level, whereas day 9 showed a decrease in expression (7742.9 AIU), a 51% increase to baseline (Figure 2 ). 
PDGF gene transcription
RT-PCR showed the highest increase in PDGF mRNA levels on day 2, followed by day 4 (Figures 3a and b) .
The levels of PDGF RNA were significantly elevated on day 2 vs control and day 2 vs day 8 and day12 ( Figure 3b ).
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PDGF gene translation
ELISA showed highest PDGF protein levels on days 2 and 4; however, no significance was reached when comparing these levels to control (Figure 3c ).
Clinical evaluation
Clinical evaluation was performed using planimetry and assessment scores in control wound fields and wounds treated with naked liposomes, naked PDGF, and the liposomal PDGF-cDNA ( Figure 4 ). Planimetrical evaluation of wounds revealed no significant differences in re-epithelialization on day 2 and day 4 after treatment. On day 8 after treatment, the wound fields that were treated with liposomal PDGF-cDNA showed a significantly higher rate of re-epithelialization as compared with the untreated controls (90±3 vs 81±2%, Po0.05); this significant difference persisted also at a later time point (day 12), where practically all of the wound surface in the liposomal PDGF-cDNA group was healed (98 ± 3 vs 87±2%, Po0.05, Figure 4 ). The clinical evaluations of wounds at days 2, 4, 8, and 12 (graft adherence, graft dislocation, granulation tissue level, occurrence of hypergranulation and hematoma, and fibrin deposition) showed no significant difference between the groups (data not shown). During each dressing change, we also assessed other signs of localized infection, such as occurrence of pus and redness between the wound fields. We did not observe differences between the groups; very small localized inflammatory responses, in some cases with small pockets of pus, were observed in some of the skin bridges between wound fields where staples had been inserted. The occurrence of these localized inflammations was not related to a specific therapy. No body temperature elevation was observed in any animal at any follow-up time point.
Discussion
The selection of animal models for wound-healing studies mainly depends on availability, costs, ease of handling, and investigator familiarity with the object. Therefore, rodents are often used in wound-healing studies. However, the dense layer of body hair and thin dermis and epidermis of rodents, make it hard to translate results of these studies into clinically applicable data. Furthermore, wounds in rodents heal primarily through wound contraction, not via re-epithelialization, due to an underlying muscular structure (panniculus carnosus) and a high amount of adnexal structures. For translational studies in wound healing, it is therefore paramount to choose an animal model that more closely represents human skin. Porcine skin is anatomically and physiologically similar to human skin and therefore more suitable to serve as a wound-healing model. The thickness of human epidermis is 50-120 mm, compared with 30-140 mm in the pig. 6 The vascularization of porcine skin is similar to that of human skin, 7 as is the collagen content and elasticity. 8 Both human and pig show sparse body hair, 9 similar epidermal turnover time, type of keratins, and stratum corneum. 10 In a comparative review of over 180 studies related to wound healing, Sullivan et al. 11 found concordance of 78% in the results of human and porcine wound-healing studies, vs only 53% in human and rodents. Their results suggested that the porcine model is an excellent tool for the evaluation of therapeutic agents designed for use in human wounds.
Gene therapy is defined as the insertion of a desired gene into a recipient cell resulting in the expression of a protein product. 1 The biology of wound healing is complex and involves the interaction of many different cell types, various cytokines, and growth factors. It has been shown that deficiency of growth factors, as seen in chronic wounds, result in the failure of wound closure. 12 Therefore, supplementation of wounds with recombinant growth factors seems feasible 13; however, there are many drawbacks including high cost and labor intensive production processes. There are also many barriers to the delivery of growth factors to their desired cell targets located in wound beds. Wounds are in a constant state of remodeling, consequently cells are producing various proteinases, which degrade polypeptide growth factors. 12 In a study where basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) were applied topically, only 1-9% of the total dose reached a level of 1-3 mm within the wound.
14 Recombinant PDGF-BB, the only growth factor approved for clinical use, requires a dose of 100 mg cm À2 on alternating days. 15 This is almost 50 times the active amount shown in genetic studies.
In the past decade, gene delivery with cationic liposomes has gained considerable attention. Briefly, cationic liposomes are vesicles with a positively charged surface that forms a loose complex with negatively charged DNA and protects it from degradation. After the positively charged DNA binds to the cell surface, it enters the cell (most probably through endocytosis, although other entry pathways such as fusion, lipid exchange, adsorption, and direct membrane proration have been discussed 4, 16 ), the DNA is released from the liposomes and taken up by the nucleus, 17 where ribosomes transcribe the nuclear cDNA into mRNA. The latter is then translated into protein and released upon stimulation by various intracellular and membrane-bound receptors. 18, 19 As a vector for gene therapy, liposomes have become attractive due to their non-viral composition, stability and ability to interact with the cell membrane. 17 So far, only few groups have performed studies to examine liposomal gene transfer for the delivery of various growth factors genes in wound-healing models. [20] [21] [22] The group of Sun et al. 22 performed gene transfer using acidic FGF genes, applied topically and subcutaneously to diabetic mice with incisional wounds, Gene transfer in a porcine burn model LK Branski et al and reported successful transfection and, additionally, increased wound breaking strength and improved wound quality in the treatment groups. Our group has performed multiple studies with the use of a rodent model of large scald burns. 19, 21, 23 We showed how cationic liposomal complexes alone attenuate the proinflammatory hypermetabolism and post-traumatic acute phase response. 24 In a preliminary biodistribution study using thermally injured rat skin, transfection was detected in myofibroblasts, endothelial cells, and macrophages, including multinucleate giant cells. The transfection rate reached 70-90%. 19, 21 Treatment with insulin-like growth factor-I (IGF-I) cDNA accelerated wound healing by stimulating collagen synthesis and the mitogenicity of fibroblasts and keratinocytes, 23 and showed an accelerated rate of re-epithelization and wound healing when compared with multiple other treatments, such as the naked protein, IGF-I encapsulated in liposomes, liposomes encoding the LacZ gene, or normal saline. 19, 21, 25 However, no evidence was found that the dermal injection of IGF-I cDNA complexes leads to transfection or increase in b-galactosidase or IGF-I expression in blood, liver, spleen or kidney. 19 We concluded that injection of liposomal constructs allows for specific targeting of epidermal and dermal cells, and that myofibroblasts, endothelial cells, and macrophages, which were identified to be transfected, produce biologically active IGF-I and exert autocrine, paracrine, or endocrine effects. 19, 23 Our present study takes a novel approach in topical delivery of growth factor genes to a wound bed. Using the porcine wound-healing model, 5 we examined vehicles for non-viral gene transfer. The use of the porcine wound-healing model provides us with a unique reproducible experimental setup that allows us to compare data between animals. Moreover, the porcine model gives us the ability to extrapolate potential translational benefits in humans. In this study, we were able to show with both immunohistochemical and immunofluorescence analysis how a sustained expression of b-galactosidase could be achieved at 4 and 7 days post-transfection with the LacZ-gene, with a modest decline at day 9. The use of confocal microscopy allowed us to assess different planes of each section, resulting in more accurate determination of transfection levels.
Advancing from the earlier studies, we have furthermore identified PDGF as one of the pivotal growth factors that influence wound-healing processes and accelerate re-epithelialization. PDGF was originally isolated from human platelets as a potent serum mitogen for cells of mesenchymal origin. 26 PDGF stimulates proliferation and induces chemotaxis of multiple mesenchymal cell types, including fibroblasts, endothelial cells, smooth muscle cells, monocytes, and neutrophils.
27-29 PDGF isoforms are synthesized by numerous cell types, including keratinocytes, the principal cell type in the epidermis. 30 Biologically active PDGF occurs as either a homodimer (AA or BB) or as a heterodimer (AB). The two peptide chains, designated A and B, are linked by disulfide bonds and share B60% homology at the amino acid level. The PDGF isoforms (PDGF-AA, PDGF-AB, and PDGF-BB) exert their effects by interacting with two tyrosine kinase receptors. The a-receptor (PDGF-aR) binds all three isoforms, whereas the b-receptor (PDGFbR) only binds PDGF-BB with high affinity. Most cells of the dermis express a receptor for PDGF.
In earlier studies, gene transfer with vectors containing PDGF-cDNA has been shown effective in improving the viability of skin flaps in both rat model 31 and humans. 32 Keswani et al. 33 showed significantly enhanced epithelial gap closure and increase in the formation of granulation tissue and vessel density in a mouse model after treatment with adenoviral PDGF-B cDNA. Gu et al. 34 also used adenoviral vectors to stimulate granulation tissue formation and cell proliferation with PDGF-cDNA in a rabbit wound model. To our knowledge, our study is the first report of a successful transfer of PDGF-cDNA in a large animal model with the use of a liposomal vector. In situ hybridization and enzyme-linked immunoabsorbent methods both showed concordant expression of PDGF mRNA and protein. We were furthermore able to confirm results of increased reepithelialization with the use of PGDF genes, advancing from the rodent model to the more clinically relevant large animal model of excision and autografting.
There are some limitations to this study. Wound fields of 50 cm 2 cannot be directly translated to severely burned patients, where large areas of the skin are burned and wound healing is generally compromised by the systemic response. A porcine model of delayed wound healing (aged or diabetic pig) may have more clearly shown the advantage of growth factor gene transfer. Another limitation common to non-viral vectors is the non-specific transfection of different cell types. 1 This was also the case in our study. Multiple cell types in the dermis and epidermis showed b-galactosidase expression. We did not quantify the rates of different transfected cells but saw that b-galactosidase was mostly expressed by fibroblasts and epithelial cells. 
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In summary, our study showed effective gene transfection of wound beds after injection of liposomal vectors in the porcine wound-healing model. It is clear that these vectors remain viable even in the harsh wound environment. Further studies are necessary to determine whether a specific cell type is preferentially transfected in the wound and to determine the ability of wound sites to express growth factors as a result of gene therapy. This study determines the possibility of wound transfection with the LacZ reporter gene. More studies are needed to prove the concept of wound-healing acceleration by growth factor gene transfection.
Materials and methods
Animal model and treatment groups
A porcine model of burn, excision, and grafting with meshed autologous skin was developed by our group to serve as a tool in burn research and mimicking the clinical scenario. 5 The project was approved by the Animal Care and Use Committee of the University of Texas Medical Branch (Protocol no. 99-01-003). This study was conducted in the large animal research facility of the Shriners Hospitals for Children and the University of Texas Medical Branch. Housing and animal care were provided according to the National Research Council guidelines.
Surgical and burn procedures were performed as described earlier. 5 Briefly, class A 30-45 kg (3-4 months old) Yorkshire pigs were purchased at a single breeding farm, housed individually at the Animal Resource Facility for at least 1 week for acclimatization, and transferred to our laboratory for conduction of experiments. All animals received standard porcine diet (LabDiet 5084, PMI Nutrition, Henderson, CO, USA) once daily, water ad libitum, and were fasted overnight before procedures. After pre-medication by intramuscular injection of Ketamine and Xylazine, animals were intubated and inhalative anesthesia delivered by isoflurane in a 2:1 oxygen:nitrous oxide mixture. A venous catheter was placed into the right jugular vein and remained in place for the entire length of the experiment.
Contact burns were created by placing a heated custom-made aluminum bar on the dorsum of the animal, as described earlier. 5 Briefly, the bar was heated to 200 1C with a Meeker gas burner, placed on the animal for 30 s at constant pressure, creating burn sites of B40 cm 2 each with 4 cm between each site or from the spine. The total burn size did not exceed 15% of the entire body surface area. The animals had free access to fluids directly postoperatively. To mimic the clinical situation, the burn was excised in healthy tissue to the level of the underlying muscular fascia 24 h after the injury, leaving the fascia intact. The average size of the resulting defects was B50 cm 2 . Before graft harvesting, skin was lubricated with Jelonet gauze (Smith&Nephew, Hull, UK) to facilitate the operation of the electric Padgett dermatome (Integra Lifesciences, Plainsboro, NJ, USA). Split-thickness skin grafts (0.4 mm thickness) were harvested, meshed at a ratio of 1:3 and trimmed to the size of the defects. Tisseel VH, a physiological coarse-type two-component fibrin sealant 35 (Baxter Healthcare, Deerfield, IL, USA), was used to attach the skin grafts. Using a two-syringe application device and a pressure controlled spray system (Duploject and Tissomat, Baxter Healthcare), B0.05 ml cm À2 of FS was applied to the wound bed, which resulted in a homogenous, thin layer of tissue glue. A multilayer dressing that protected wounds from contamination was used after the grafting procedure. Dressing changes were performed at days 2, 5, 7, and 9. At day 14, the animals were killed. During surgical procedures and dressing changes, heart rate and oxygen saturation were monitored. Intraoperatively, fluids were substituted with Ringer's Lactate solution at 5 ml kg À1 h À1 via the implanted venous jugular catheter. Postoperative analgesia was provided with transdermal fentanyl patches (Duragesic 25, Ortho-McNeil-Janssen Pharmaceuticals, Titusville, NJ, USA) and with oral nonsteroidal analgesics (Ibuprofen 500 mg PO). Intravenous perioperative antimicrobial prophylaxis was provided with cephalosporin (Cefazol 1 g, Bosch Pharmaceuticals, Karachi, Pakistan), and oral postoperative antimicrobial prophylaxis was continued for 7 days with levofloxacin 500 mg tablets (Levaquin, Ortho-McNeil-Janssen Pharmaceuticals). Before the study, wound sites were randomly assigned to the following groups:
B-Gal transfection: Fields were randomized to receive subcutaneous injections of LacZ-cDNA (n ¼ 8) or empty liposomes (n ¼ 8). Growth factor gene transfection: Fields were randomized to receive either empty liposomes (n ¼ 6), naked PDGF-cDNA (n ¼ 6), liposomal PDGF-cDNA (n ¼ 6), or no therapy (n ¼ 6).
In our porcine wound-healing model, differences in wound healing and graft take may occur between wounds located more medial and cranial as opposed to those in a more lateral and caudal position, due to the proximity to the hind leg with more rubbing of the dressing material and permanent movement of the wound fields. To minimize the influence of this variable, we made sure that the most lateral and caudal wound fields would have a sufficient distance from the hind legs, and randomized the wound fields to treatments in two groups, so that each group would include an equal number of cranial and caudal wound fields.
Preparation of liposomal gene constructs
The cDNA constructs consisted of LacZ-cDNA coding for b-galactosidase or PDGF-cDNA coding for PDGF with a cytomegalovirus-driven promoter. Constructs were prepared at the University of Texas Medical Branch Sealy Center for Molecular Science Recombinant DNA core facility. Liposomal vectors were formulated from 1:1 (M/M) DMRIE (1,2-dimyristyloxypropyl-3-dimethylhydroxyl ethyl ammonium bromide) and cholesterol suspended in membrane-filtered water (Invitrogen, Carlsbad, CA, USA). This reagent interacts spontaneously with cDNA to form the lipid cDNA complex. To create the solution for subcutaneous injection, LacZ or PDGF-cDNA stock solution was diluted with PBS. Undiluted DMRIE Stock was then added drop by drop into the vial to reach a cDNA:liposome weight ration of 1:3. The solution was then gently mixed by drawing up and down 3-5 times in a syringe, and incubated at room temperature for 6-7 min.
Immunohistochemistry and immunofluorescence
Biopsies from each wound field were taken at each dressing change, fixed in formalin solution, and mounted in paraffin from which 10 mm sections were cut. These samples were mounted on Fischer Superfrost Plus Slides overnight at 37 1C and underwent deparafinization followed by heated antigen retrieval using citrated buffer. Endogenous peroxidases were quenched by incubation with 3% hydrogen peroxide in methanol. After incubation with goat serum for 1 h, sections were incubated overnight at 4 1C with a 1:10 000 dilution of rabbit polyclonal antibody to recombinant full length b-galactosidase (ab616; Abcam, Cambridge, MA, USA). Following overnight incubation, sections were prepared for immunohistochemical and immunofluorescent evaluation of transfection by quantifying expression of b-galactosidase. For immunohistochemical evaluation, a biotinylated goat anti-rabbit antibody and avidinbiotin complex (ABC AK-5001; Vector Laboratories, Burlingame, CA, USA) was used as secondary antibody. Vector Red (SK-5001; Vector Laboratories) was used as the substrate chromogen. Nuclei were counterstained with hematoxylin.
For immunofluorescence, a 1:1000 dilution of goat anti-rabbit Fab' conjugated to fluorescein (FITC; Alexa Fluor 488; Molecular Probes-Invitrogen) was used as a secondary antibody. Following a 2-h incubation time, nuclei were counterstained and mounted (Vectasheild Mounting Medium with DAPI; H-1200; Vector Laboratories). Transfection rate was calculated from three random high-power field images at Â 400 magnification using a confocal microscope (Zeiss LSM 510 UV META Laser Scanning Confocal Microscop, Jena, Germany). Control slides were used to determine baseline fluorescence and establish microscope settings that were used in determining fluorescence levels in treatment slides. Using the Metamorph 6 software suite (Molecular Devices, Sunnyvale, CA, USA) transfection levels were determined by counting all cells in the field, recording the intensity of fluorescence surrounding each cell, and calculating the total average fluorescence. The level of total average fluorescence was then normalized by expressing it as percentage change to control.
RT-PCR and ELISA
Approximately 2 g of each snap-frozen pig skin tissue was used to prepare RNA samples. Total RNA was extracted using Qiazol (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. RNA pellets were dissolved in RNase-free water and the concentration was calculated from absorbance at 260 nm. Each total RNA (10 g) was treated with DNase I (RNase-free, New England Biolabs, Ipswich, MA, USA) at 37 1C for 10 min to eliminate contaminated genomic DNA. After the reverse transcriptase reaction was performed with oligo-dT primers and M-MLV reverse transcriptases (Promega, Madison, WI, USA) at 42 1C for 60 min, transfected PDGF was amplified by an iCycler (BioRad, Hercules, CA, USA) using the human PDGF specific primer set (final concentration; 250 nM) and 0.625 U of GoTaq DNA polymerase (Promega) in a final reaction volume of 25 ml. Porcine b-actin was used as a loading control. 36 0 . PDGF protein concentration was determined using standard ELISA techniques. A Milliplex MAP Multiplex kit (Millipore, Billerica, MA, USA) for PDGF-AB was used in this experimental setup. Proteins were extracted and samples were applied to a 96-well plate and the kit run according to the manufacturer's guidelines. RT-PCR and ELISA analysis were performed on numbered samples that did not reveal the group allocation by members of our research group who did not take part in the planning and conduction of the large animal experiments.
Planimetry and clinical evaluation
During each dressing change and before euthanasia, standardized digital photographs of the wound fields were obtained (Cybershot Digital Camera; Sony, Tokyo, Japan) and evaluated using planimetric software, as described earlier. 5 For correct measurement of the absolute area of each parameter by planimetry, a calibrated benchmark was positioned adjacent to each wound site during photographing. All counting, specifically in the assessment of wound fields (planimetry) and the assessment of immunofluorescence, were performed by at least two observers who were blinded to the treatment.
Clinical evaluation of wounds was conducted using a scale from 0 to 5, as described earlier. 5 Parameters of the clinical evaluation included graft adherence, graft dislocation, granulation tissue level, occurrence of hypergranulation and hematoma, and fibrin deposition. This evaluation was conducted independently by the two investigators during each dressing change.
Statistical analysis
Statistical analysis was performed using SigmaStat software Version 3.11. (Systat Software, Chicago, IL, USA). Macroscopic scoring data were evaluated using the Mann-Whitney rank sum test for non-parametric comparisons. Student's t-test was used to evaluate differences in total and remaining wound sizes, as well as in the measurements of dermal and epidermal thickness. Statistical significance was accepted at a level of Po0.05.
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